Thursday, April 1, 2010

domperidone


dome-PER-i-done


Available Dosage Forms:


  • Tablet

Therapeutic Class: Antiemetic


Pharmacologic Class: Dopamine Antagonist


Uses For domperidone

Domperidone is a medicine that increases the movements or contractions of the stomach and bowel. Domperidone is also used to treat nausea and vomiting caused by other drugs used to treat Parkinson's Disease.


Domperidone is to be given only by or under the immediate supervision of your doctor.


Before Using domperidone


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For domperidone, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to domperidone or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Children—Studies on domperidone have been done only in adult patients, and there is no specific information comparing use of domperidone in children with use in other age groups.


Geriatric


Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing the use of domperidone in the elderly with use in other age groups.


Breast Feeding


Studies suggest that this medication may alter milk production or composition. If an alternative to this medication is not prescribed, you should monitor the infant for side effects and adequate milk intake.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving domperidone, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using domperidone with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Lithium

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of domperidone. Make sure you tell your doctor if you have any other medical problems, especially:


  • Bleeding from the stomach or other problems involving the bowels

  • Pituitary (brain) tumor

  • Liver disease

  • Medicine sensitivity to domperidone

Proper Use of domperidone


Dosing


The dose of domperidone will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of domperidone. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage form (tablets):
    • Treatment of gastrointestinal motility disorders:
      • Adults—10 milligrams (mg) three to four times daily. Some patients may require higher doses up to 20 mg three or four times daily.


    • Nausea and vomiting:
      • Adults—20 milligrams (mg) three to four times daily.



Missed Dose


If you miss a dose of domperidone, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using domperidone


It is very important that your doctor check your progress at regular visits. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it.


If your symptoms do not improve within a few days or if they become worse, check with your doctor.


domperidone Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Symptoms of overdose

Get emergency help immediately if any of the following symptoms of overdose occur:


  • Difficulty in speaking

  • disorientation

  • dizziness

  • fainting

  • irregular heartbeat

  • light-headedness

  • loss of balance or muscle control

Check with your doctor immediately if any of the following side effects occur:


Less common
  • Loss of balance or muscle control

  • swelling of the mouth

Rare
  • Fast, irregular, pounding, or racing heartbeat or pulse

  • swelling of face, hands, lower legs, or feet

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Less common
  • Breast milk flowing from the nipple

  • dry mouth

  • swelling of the breast in the male

  • headache

  • hives

  • hot flashes

  • itching of skin

  • itching, redness, pain, or swelling of eye

  • menstrual irregularities

  • pain in the breast

Rare
  • Change in need to urinate

  • change in appetite

  • constipation

  • diarrhea

  • burning, difficult, or painful urination

  • difficulty in speaking

  • dizziness

  • drowsiness

  • heartburn

  • irritability

  • lack or loss of strength

  • leg cramps

  • mental dullness

  • nervousness

  • palpitations

  • sluggishness

  • stomach cramps

  • thirst

  • tiredness

  • weakness


The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

Monday, March 22, 2010

Azilect


Azilect is a brand name of rasagiline, approved by the FDA in the following formulation(s):


AZILECT (rasagiline mesylate - tablet; oral)



  • Manufacturer: TEVA

    Approval date: May 16, 2006

    Strength(s): EQ 0.5MG BASE, EQ 1MG BASE [RLD]

Has a generic version of Azilect been approved?


No. There is currently no therapeutically equivalent version of Azilect available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azilect. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
    Patent 5,387,612
    Issued: February 7, 1995
    Inventor(s): Youdim; Mussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim
    Assignee(s): Teva Pharmaceutical Industries Ltd.
    Technion Research and Development Foundation Ltd.
    R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
    Patent expiration dates:

    • February 7, 2012
      ✓ 
      Patent use: TREATMENT OF PARKINSON'S DISEASE




  • Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
    Patent 5,453,446
    Issued: September 26, 1995
    Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim
    Assignee(s): Teva Pharmaceutical Industries, Ltd.
    Technion Research and Development Foundation Ltd.
    R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
    Patent expiration dates:

    • February 7, 2017
      ✓ 
      Patent use: TREATMENT OF PARKINSON'S DISEASE




  • R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them
    Patent 5,457,133
    Issued: October 10, 1995
    Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim
    Assignee(s): Teva Pharmaceutical Industries Ltd.
    Technion Research and Development Foundation Ltd.
    R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
    Patent expiration dates:

    • February 7, 2012
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
    Patent 5,532,415
    Issued: July 2, 1996
    Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim & Veinberg; Alex
    Assignee(s): Teva Pharmaceutical Industries Ltd.
    Technion Research and Development Foundation Ltd.
    The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
    Patent expiration dates:

    • July 2, 2013
      ✓ 
      Drug substance




  • Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
    Patent 5,786,390
    Issued: July 28, 1998
    Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim & Veinberg; Alex
    Assignee(s): Teva Pharmaceutical Industries Ltd.
    Technion Research and Development Foundation Ltd.
    The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.
    Patent expiration dates:

    • February 7, 2012
      ✓ 
      Drug product




  • Stable compositions containing N-propargyl-1-aminoindan
    Patent 6,126,968
    Issued: October 3, 2000
    Inventor(s): Peskin; Tirtsah Berger & Caciularu; Fanny
    Assignee(s): Teva Pharmaceutical Industries, Ltd.
    A pharmaceutical composition comprising as active ingredient a racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one pentahydric or hexahydric alcohol. Optionally the composition may contain citric acid and magnesium stearate.
    Patent expiration dates:

    • September 18, 2016
      ✓ 
      Drug product




  • Rasagiline formulations and processes for their preparation
    Patent 7,572,834
    Issued: August 11, 2009
    Inventor(s): Sterling; Jeffrey & Lerner; David & Rosen; Harel & Bronov; Leonid & Medini-Green; Dalia & Iosefzon; Berta & Berger-Peskin; Tirtsah & Lidor-Hadas; Ramy & Bahar; Eliezer
    Assignee(s): Teva Pharmaceutical Industries, Ltd.
    The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.
    Patent expiration dates:

    • December 5, 2026
      ✓ 
      Drug product




  • Rasagiline formulations of improved content uniformity
    Patent 7,815,942
    Issued: October 19, 2010
    Inventor(s): Peskin; Tirtza Berger
    Assignee(s): Teva Pharmaceutical Industries, Ltd.
    Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.
    Patent expiration dates:

    • August 27, 2027
      ✓ 
      Patent use: TREATMENT OF PARKINSON'S DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 16, 2011 - NEW CHEMICAL ENTITY

See also...

  • Azilect Consumer Information (Drugs.com)
  • Azilect Consumer Information (Wolters Kluwer)
  • Azilect Consumer Information (Cerner Multum)
  • Azilect Advanced Consumer Information (Micromedex)
  • Azilect AHFS DI Monographs (ASHP)
  • Rasagiline Consumer Information (Wolters Kluwer)
  • Rasagiline Consumer Information (Cerner Multum)
  • Rasagiline Advanced Consumer Information (Micromedex)
  • Rasagiline Mesylate AHFS DI Monographs (ASHP)

Monday, March 15, 2010

Acular Gervasi




Acular Gervasi may be available in the countries listed below.


Ingredient matches for Acular Gervasi



Ketorolac

Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Acular Gervasi in the following countries:


  • Spain

International Drug Name Search

Friday, March 12, 2010

Migriz




Migriz may be available in the countries listed below.


Ingredient matches for Migriz



Rizatriptan

Rizatriptan is reported as an ingredient of Migriz in the following countries:


  • Bangladesh

International Drug Name Search

Thursday, March 11, 2010

HCTad




HCTad may be available in the countries listed below.


Ingredient matches for HCTad



Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of HCTad in the following countries:


  • Germany

International Drug Name Search

Saturday, March 6, 2010

Mesna GP Pharm




Mesna GP Pharm may be available in the countries listed below.


Ingredient matches for Mesna GP Pharm



Mesna

Mesna is reported as an ingredient of Mesna GP Pharm in the following countries:


  • Peru

International Drug Name Search

Thursday, March 4, 2010

Razon




Razon may be available in the countries listed below.


Ingredient matches for Razon



Pantoprazole

Pantoprazole is reported as an ingredient of Razon in the following countries:


  • Tunisia

International Drug Name Search